Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Shelby D ReedYanhong LiJose LealLarry RadicanAmanda I AdlerJoakim AlfredssonJohn B BuseJennifer B GreenKeith D KaufmanAxel RiefflinFrans Van de WerfEric D PetersonAlastair M GrayRury R Holmannull null

Published in: Diabetes, obesity & metabolism (2018)

Lower hospitalization rates across time with sitagliptin slightly offset sitagliptin treatment costs over 3 years in type 2 diabetes patients at high risk for cardiovascular events.

Keyphrases

type diabetes
end stage renal disease
cardiovascular events
ejection fraction
chronic kidney disease
newly diagnosed
cardiovascular disease
peritoneal dialysis
healthcare
prognostic factors
coronary artery disease
clinical trial
skeletal muscle
phase iii
patient reported outcomes
open label
patient reported